PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Protagonist Therapeutics, Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$134.44+5.69 (+4.42%)

Close on Oct 19, 2026

Market cap: $9.55B
P/E (TTM): 130.5
Dividend yield: –

Protagonist Therapeutics, Inc income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31
Revenue	46	434	60	27	27	29	0.23	31	20	–	–	–
Research & Development	159	138	120	126	126	75	65	59	46	26	12	7.46
General & Administrative	45	43	33	32	27	19	16	14	12	6.96	2.96	1.86
Operating Expenses	204	182	154	158	153	93	81	73	58	33	15	9.32
Operating Income	-158	253	-94	-131	-126	-65	-81	-42	-38	-33	-15	-9.32
Interest Expense	–	–	–	–	–	0.60	0.17	–	–	–	–	–
Interest & Investment Income	29	26	15	4.06	0.44	0.90	2.81	2.57	0.95	0.24	0.02	0.02
Other Non-Operating Income	0.03	0.25	-0.20	-0.08	-0.15	-0.05	0.00	-0.02	-0.01	-0.03	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	–	–	-0.01	–	0.06	-0.03	–	–
Pretax Income	-129	279	-79	-127	-126	-65	-78	-40	-37	-37	-15	–
Income Tax Expense	0.84	4.22	0	0	0	1.31	-0.69	-0.80	0	0	0	0
Net Income incl. Noncontrolling Interests	-130	275	-79	-127	-126	-66	-77	-39	-37	-37	-15	–
Net Income	-130	275	-79	-127	-126	-66	-77	-39	-37	-37	-15	-11
Net Income to Common	–	–	–	–	–	–	–	-39	-37	-38	-15	-11
EPS (Basic)(per share)	-2.05	4.47	-1.39	-2.60	-2.71	-1.92	-2.98	-1.74	-2.09	-5.80	-59.32	-49.38
EPS (Diluted)(per share)	-2.05	4.23	-1.39	-2.60	-2.71	-1.92	-2.98	-1.74	-2.09	-5.80	-59.32	-49.38
Shares Outstanding (Basic, Weighted)(shares)	64	62	57	49	46	34	26	22	18	6.50	0.25	0.23
Shares Outstanding (Diluted, Weighted)(shares)	64	65	57	49	46	34	26	22	18	6.50	0.25	0.23
EBITDA	-157	254	-93	-130	-125	-64	-80	-42	-37	-32	-15	-9.06

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: 20.7%
Net margin: 29.4%
Return on equity, FY2025: -20.2%

Financial strength

Current ratio: 21.71
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 1129.8%

Valuation

P/E ratio: 130.5
Price to sales: 33.85
Price to book: 11.34
Dividend yield: –